Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study☆,☆☆,★
Section snippets
Study design
This double-blind, randomized, placebo-controlled, parallel-group, dose-titration, outpatient study was conducted at 21 sites in the United States on patients with stage I and stage II essential hypertension. The study was divided into 4 periods. The prequalification period was a 2- to 4-week washout period during which antihypertensive medication was discontinued and placebo was given under single-blind conditions. The next was a qualification period of 2 weeks during which the patients took
Results
Of the 262 patients enrolled in the study, 132 were randomly assigned to receive tasosartan and 130 to receive placebo. Table I shows the demographic characteristics for the tasosartan and placebo groups.
Characteristics Tasosartan (n = 132) Placebo (n = 130) Age (yr) 52.2 ± 9.6 52.5 ± 9.7 Range (23-69) (26-69) Sex (No. of patients) Male 88 92 Female 44 38 Race (No. of patients) White 105 100 Black 18 23 Hispanic 6 4 Asian 2 2 Other 1 1 Weight (kg) 86.0 ± 15.3 88.3 ± 17 Height (cm) 173.0 ± 9.1 171.9 ± 11.0
Discussion
Pharmacologic interruption of the renin-angiotensin system has been shown to be extremely useful in the management of hypertension.12, 13, 14 In addition to reducing blood pressure, reduction of angiotensin II activity has been associated with regression of left ventricular hypertrophy,15 improved arterial compliance,16 increased insulin sensitivity,17, 18 and reduction in proteinuria in patients with moderate renal function impairment.19
ACEIs, which until recently have been the only clinically
References (29)
- et al.
Tasosartan: a once-a-day angiotensin II (AII) receptor antagonist with a documented dose-response
Am J Hypertens
(1997) - et al.
Angiotensin converting enzyme inhibitors: past, present and bright future
Lancet
(1985) - et al.
Renal hemodynamic and reduction of proteinuria by a vasodilatory beta blocker versus an ACE inhibitor
Kidney Int
(1992) - et al.
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
Am J Cardiol
(1995) Historical perspective on renin system blockade in the treatment of hypertension
Am J Hypertens
(1992)- et al.
The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis
- et al.
Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure
J Clin Pharmacol
(1994) - et al.
Persistent dry cough with enalapril, incidence depends on methods used
J Hum Hypertens
(1990) - et al.
Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology
Ann Intern Med
(1992) - et al.
Pathophysiology of silent myocardial ischemia during daily life: hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring
Circulation
(1990)
Lisinopril and enalapril in hypertension: a comparative study using ambulatory monitoring
J Hum Hypertens
Antihypertensive treatment and trough:peak ratio: general considerations
J Hypertens
Pyrido [2,3-d] pyrimidine angiotensin II antagonists
J Med Chem
Angiotensin II (AII) blockade effect of ANA-756 in normal volunteers
Clin Pharmacol Ther
Cited by (0)
- ☆
Supported by a grant from Wyeth-Ayerst Research.
- ☆☆
Reprint requests: Joel M. Neutel, MD, 505 S Main St, Suite 1025, Orange, CA 92868.
- ★
4/1/90817